Janet B. McGill
Washington University in St. Louis
212 Papers
924 Citations
Janet B. McGill is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Diabetes mellitus & Medicine. The author has an hindex of 61, co-authored 182 publications.
Chat about Author
Papers
Catheter obstruction with continuous subcutaneous insulin infusion. Effect of insulin concentration.
TL;DR: It is hypothesized that insulin aggregation and occlusion would occur less often if the flow rate of insulin solution was greater through the infusion set and to test this hypothesis, 10 patients using CSII were studied and Occlusion rates with two different concentrations of insulin were examined.
Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
Mark E. Cooper,Vlado Perkovic,Janet B. McGill,Per-Henrik Groop,Per-Henrik Groop,Christoph Wanner,Julio Rosenstock,Uwe Hehnke,Hans-Juergen Woerle,Maximilian von Eynatten +9 more
TL;DR: Linagliptin was not associated with increased kidney disease risk in patients with type 2 diabetes and the potential of this drug to improve kidney disease outcomes warrants further investigation.
Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients
TL;DR: Vasoconstricting beta-blocker use is associated with a reduction in HDL cholesterol, higher triglyceride, total cholesterol and LDL cholesterol levels, whereas carvedilol, a vasodilating beta‐blocker, has not been associated with these effects.
β-Blocker use and diabetes symptom score: results from the GEMINI study
Janet B. McGill,George L. Bakris,Vivian Fonseca,Philip Raskin,Franz H. Messerli,Robert A. Phillips,Richard E. Katholi,Jackson T. Wright,Malini Iyengar,Karen M. Anderson,Mary Ann Lukas,M. R. Dalal,David S.H. Bell +12 more
TL;DR: The GEMINI trial compared the metabolic effects of two β‐blockers in people with type 2 diabetes and hypertension treated with renin–angiotensin system (RAS) blockade and found differences in metabolic outcomes.
Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy
Julia A. Breyer,Raymond P. Bain,Joni Evans,N. Stanley Nahman,Edmund J. Lewis,Melisa Cooper,Janet B. McGill,Tomas Berl +7 more
TL;DR: A number of clinical and laboratory risk factors are identified that can predict which patients with insulin-dependent diabetes with established nephropathy are more likely to sustain a clinically important decrease in renal function over a median follow-up of three years.